Modus Therapeutics appoints Ellen Donnelly as chief executive

Dr Ellen Donnelly, former head of clinical operations of the neuroscience and pain therapeutic area at Pfizer (NYSE: PFE), has been appointed as chief executive officer at Modus Therapeutics.

Modus, which focuses on developing treatments for sickle cell disease (SCD), is owned by Swedish biotech firm Karolinska Development (STO: KDEV).

At Pfizer, she held numerous leadership positions in clinical operations, project and portfolio management, and research.

Prior to her time at Pfizer, Dr Donnelly worked in biotech and management consulting. She received her PhD from Yale University.

Dr Donnelly said: "I am thrilled to join Modus at this important time for the company. The high unmet medical needs of SCD patients require novel therapeutic options, and I look forward to working with patients and their families to ensure the best possible outcomes for this disease, as we further develop sevuparin for SCD."